Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TR2-H5257 | Human | Human TREM2 (19-131) Protein, Fc Tag |
|
|
|
TR2-H5254 | Human | Human TREM2 Protein, Fc Tag |
|
|
|
TR2-C52H3 | Cynomolgus | Cynomolgus TREM2 Protein, His Tag |
|
|
|
TR2-M5254 | Mouse | Mouse TREM2 Protein, Fc Tag |
|
|
|
TR2-H5256 | Human | Human TREM2 Protein, Mouse IgG2a Fc Tag |
|
|
|
TR2-M52H3 | Mouse | Mouse TREM2 Protein, His Tag |
|
|
|
TR2-H52H5 | Human | Human TREM2 Protein, His Tag |
|
|
|
TR2-H82E7 | Human | Biotinylated Human TREM2 Protein, His,Avitag™ |
|
|
Anti-TREM2 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TREM2, His Tag (Cat. No. TR2-H52H5) with an affinity constant of 95.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AL-002 | AL-002a; AL-002-a; AL-002 | Phase 2 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
Iluzanebart | VGL-101; VGL 101 | Phase 2 Clinical | Amgen Inc | Posterior Leukoencephalopathy Syndrome; Nerve Degeneration | Details |
DNL-919 | DNL-919; TAK-920 | Phase 1 Clinical | Denali Therapeutics Inc | Alzheimer Disease | Details |
VG-3927 | VG-3927 | Phase 1 Clinical | Vigil Neuroscience Inc | Alzheimer Disease | Details |
AL-002 | AL-002a; AL-002-a; AL-002 | Phase 2 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
Iluzanebart | VGL-101; VGL 101 | Phase 2 Clinical | Amgen Inc | Posterior Leukoencephalopathy Syndrome; Nerve Degeneration | Details |
DNL-919 | DNL-919; TAK-920 | Phase 1 Clinical | Denali Therapeutics Inc | Alzheimer Disease | Details |
VG-3927 | VG-3927 | Phase 1 Clinical | Vigil Neuroscience Inc | Alzheimer Disease | Details |
This web search service is supported by Google Inc.